| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Papers In Press, published online ahead of print January 18, 2002
Department of Molecular Oncology, Genentech, Inc., South San Francisco, CA 94080
Corresponding Author: dixit{at}gene.com
Inhibitors of apoptosis (IAPs) physically interact with a variety of pro-apoptotic proteins and inhibit apoptosis induced by diverse stimuli. X-linked IAP (X-IAP) is a prototype IAP family member that inhibits several caspases, the effector proteases of apoptosis. The inhibitory activity of X-IAP is regulated by SMAC, a protein that is processed to its active form upon receipt of a death stimulus. Cleaved SMAC binds X-IAP and antagonizes its anti-apoptotic activity. Here we show that melanoma IAP (ML-IAP), a potent anti-cell death protein and caspase inhibitor, physically interacts with SMAC through its BIR domain. In addition to binding full-length SMAC, ML-IAP BIR associates with SMAC peptides that are derived from the amino-terminus of active, processed SMAC. This high affinity interaction is very specific and can be completely abolished by single amino acid mutations either in the amino terminus of active SMAC or in the BIR domain of ML-IAP. In cells expressing ML-IAP and X-IAP, SMAC coexpression or addition of SMAC peptides abrogates the ability of the IAPs to inhibit cell death. These results demonstrate the feasibility of using SMAC peptides as a way to sensitize IAP-expressing cells to pro-apoptotic stimuli such as chemotherapeutic agents.
J. Biol. Chem, 10.1074/jbc.M112045200
Submitted on December 18, 2001
Revised on January 18, 2002
Accepted on January 18, 2002
SMAC negatively regulates the anti-apoptotic activity of ML-IAP
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  J. N. Dynek, S. M. Chan, J. Liu, J. Zha, W. J. Fairbrother, and D. Vucic Microphthalmia-Associated Transcription Factor Is a Critical Transcriptional Regulator of Melanoma Inhibitor of Apoptosis in Melanomas Cancer Res., May 1, 2008; 68(9): 3124 - 3132. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Vucic and W. J. Fairbrother The Inhibitor of Apoptosis Proteins as Therapeutic Targets in Cancer Clin. Cancer Res., October 15, 2007; 13(20): 5995 - 6000. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Chang and A. D. Schimmer Livin/melanoma inhibitor of apoptosis protein as a potential therapeutic target for the treatment of malignancy Mol. Cancer Ther., January 1, 2007; 6(1): 24 - 30. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Varfolomeev, S. M. Wayson, V. M. Dixit, W. J. Fairbrother, and D. Vucic The Inhibitor of Apoptosis Protein Fusion c-IAP2{middle dot}MALT1 Stimulates NF-{kappa}B Activation Independently of TRAF1 AND TRAF2 J. Biol. Chem., September 29, 2006; 281(39): 29022 - 29029. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. P. Eckelman and G. S. Salvesen The Human Anti-apoptotic Proteins cIAP1 and cIAP2 Bind but Do Not Inhibit Caspases J. Biol. Chem., February 10, 2006; 281(6): 3254 - 3260. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Gong, N Chen, Q Zhou, B Yang, Y Wang, and X Wang Melanoma inhibitor of apoptosis protein is expressed differentially in melanoma and melanocytic naevus, but similarly in primary and metastatic melanomas J. Clin. Pathol., October 1, 2005; 58(10): 1081 - 1085. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-B. Qiu and A. L. Goldberg The Membrane-associated Inhibitor of Apoptosis Protein, BRUCE/Apollon, Antagonizes Both the Precursor and Mature Forms of Smac and Caspase-9 J. Biol. Chem., January 7, 2005; 280(1): 174 - 182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Wang, M. Cuddy, T. Samuel, K. Welsh, A. Schimmer, F. Hanaii, R. Houghten, C. Pinilla, and J. C. Reed Cellular, Biochemical, and Genetic Analysis of Mechanism of Small Molecule IAP Inhibitors J. Biol. Chem., November 12, 2004; 279(46): 48168 - 48176. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Qiuping, X. Jei, J. Youxin, J. Wei, L. Chun, W. Jin, W. Qun, L. Yan, H. Chunsong, Y. Mingzhen, et al. CC Chemokine Ligand 25 Enhances Resistance to Apoptosis in CD4+ T Cells from Patients with T-Cell Lineage Acute and Chronic Lymphocytic Leukemia by Means of Livin Activation Cancer Res., October 15, 2004; 64(20): 7579 - 7587. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Rashmi, S. Kumar, and D. Karunagaran Ectopic expression of Bcl-XL or Ku70 protects human colon cancer cells (SW480) against curcumin-induced apoptosis while their down-regulation potentiates it Carcinogenesis, October 1, 2004; 25(10): 1867 - 1877. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Pennati, M. Binda, M. De Cesare, G. Pratesi, M. Folini, L. Citti, M. G. Daidone, F. Zunino, and N. Zaffaroni Ribozyme-mediated down-regulation of survivin expression sensitizes human melanoma cells to topotecan in vitro and in vivo Carcinogenesis, July 1, 2004; 25(7): 1129 - 1136. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Rashmi, S. Kumar, and D. Karunagaran Ectopic expression of Hsp70 confers resistance and silencing its expression sensitizes human colon cancer cells to curcumin-induced apoptosis Carcinogenesis, February 1, 2004; 25(2): 179 - 187. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Fu, Y. Jin, and L. J. Arend Smac3, a Novel Smac/DIABLO Splicing Variant, Attenuates the Stability and Apoptosis-inhibiting Activity of X-linked Inhibitor of Apoptosis Protein J. Biol. Chem., December 26, 2003; 278(52): 52660 - 52672. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Krajewska, S. Krajewski, S. Banares, X. Huang, B. Turner, L. Bubendorf, O.-P. Kallioniemi, A. Shabaik, A. Vitiello, D. Peehl, et al. Elevated Expression of Inhibitor of Apoptosis Proteins in Prostate Cancer Clin. Cancer Res., October 15, 2003; 9(13): 4914 - 4925. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Nachmias, Y. Ashhab, V. Bucholtz, O. Drize, L. Kadouri, M. Lotem, T. Peretz, O. Mandelboim, and D. Ben-Yehuda Caspase-Mediated Cleavage Converts Livin from an Antiapoptotic to a Proapoptotic Factor: Implications for Drug-Resistant Melanoma Cancer Res., October 1, 2003; 63(19): 6340 - 6349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Song, X. Yao, and M. Wu Direct Interaction between Survivin and Smac/DIABLO Is Essential for the Anti-apoptotic Activity of Survivin during Taxol-induced Apoptosis J. Biol. Chem., June 13, 2003; 278(25): 23130 - 23140. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Schmollinger, R. H. Vonderheide, K. M. Hoar, B. Maecker, J. L. Schultze, F. S. Hodi, R. J. Soiffer, K. Jung, M. J. Kuroda, N. L. Letvin, et al. Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction PNAS, March 18, 2003; 100(6): 3398 - 3403. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Springs, V. M. Diavolitsis, J. Goodhouse, and G. L. McLendon The Kinetics of Translocation of Smac/DIABLO from the Mitochondria to the Cytosol in HeLa Cells J. Biol. Chem., November 22, 2002; 277(48): 45715 - 45718. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. R. Arnt, M. V. Chiorean, M. P. Heldebrant, G. J. Gores, and S. H. Kaufmann Synthetic Smac/DIABLO Peptides Enhance the Effects of Chemotherapeutic Agents by Binding XIAP and cIAP1 in Situ J. Biol. Chem., November 8, 2002; 277(46): 44236 - 44243. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |
